ICU Medical, Incorporated ICUI- ICU Medical, Inc. is engaged in the development, manufacture and sale of disposable medical connection systems for use in vascular therapy applications. The Company' devices are designed to protect patients from catheter-related bloodstream infections and healthcare workers from exposure to diseases through accidental needlesticks.
China Kanghui Holdings KH- China Kanghui Holdings is a holding company and conducts all of its business through its two wholly owned subsidiaries in China, Changzhou Kanghui Medical Innovation Co., Ltd. (Changzhou Kanghui) and Beijing Libeier. The Company is a domestic developer, manufacturer and marketer of orthopedic implants in People's Republic of China.
OraSure Technologies, Inc. OSUR- For the full year, analysts expect the company to post a loss of $0.15. In the year-ago period, the company reported a loss of $0.05 on sales of $18 million. In the previous quarter, the company reported a loss of $0.02, topping consensus estimates for a loss of $0.03.
Antares Pharma, Inc. AIS- As per the most recent quarterly report, the net income per share (EPS) is -0.07. It operates in Healthcare sector and belongs to Medical Equipment and Supplies industry. The organization is a pharmaceutical company that focuses on self-injection pharmaceutical products and technologies and gel-based products. The company has a 52 week high of $ 2.00 and a 52 week low of $ 1.32. Average volumes of shares traded daily are 583,955.00.
Syneron Medical Ltd. ELOS- Syneron Medical Ltd. designs, develops and markets aesthetic medical products based on its various technologies including its Electro-Optical Synergy (ELOS), technology, which uses the synergy between electrical energy, including radiofrequency (RF) energy, and optical energy to provide aesthetic medical treatments.
Fluidigm Corporation (ADR) FLDM- Fluidigm FLDM develops, manufactures and markets microfluidic systems for growth markets in the life science and agricultural biotechnology, or Ag-Bio, industries. Fluidigm's proprietary microfluidic systems consist of instruments and consumables, including chips and reagents. These systems are designed to significantly simplify experimental workflow, increase throughput and reduce costs, while providing the excellent data quality demanded by customers. Gajus Worthington, Fluidigm president and chief executive officer, and Vikram Jog, chief financial officer, will host a conference call at 2:30 p.m. PDT (5:30 p.m. EDT), May 10 to discuss Q1 financial results and operating activities. A press release outlining the financial results will be publicly distributed prior to the call.
Synergetics USA Inc. SURG- Synergetics USA, Inc. (Synergetics USA) is a medical device company. It is a supplier of precision microsurgical devices. The Company focuses on the microsurgical disciplines of ophthalmology and neurosurgery. Its distribution channels include a combination of direct and independent sales organizations and alliances with market leaders.
Winner Medical Group, Inc WWIN- Winner Medical is a leading medical disposable products manufacturer in China, with business operations consisting of manufacturing, researching, developing and marketing cotton-based medical dressings and medical disposables, as well as consumer products.
Tornier N.V. TRNX- Tornier market capitalization is $821.01M and it has 39.04M outstanding shares.Tornier B.V. (Tornier) is a global medical device company focused on surgeons that treat musculoskeletal injuries and disorders of the shoulder, elbow, wrist, hand, ankle and foot. The Company refers to these surgeons as extremity specialists. It sells this extremity specialist customer base a line of joint replacement, trauma, sports medicine and orthobiologic products to treat extremity joints. In certain international markets, it also offers joint replacement products for the hip and knee. It sells over 70 product lines in approximately 35 countries.
Delcath Systems, Inc. DCTH- Delcath Systems, Inc. (Delcath) is a development-stage company that has developed a system designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body. The Company focuses on the development of its product, the Delcath Percutaneous Hepatic Perfusion System (the Delcath PHP System), which provides regional therapy by isolating the circulatory system of the liver in order to directly deliver high doses of therapeutic agents, while controlling the systemic exposure of those agents. The Delcath PHP System is minimally invasive and repeatable.
SPECIAL DISCOUNT- SUBSCRIBE to CEOWORLD Magazine Digital Magazine & SAVE UP TO 80% OFF. Reaching more than 85,000 Chief Executive Officers and decision making executives who serve on the boards of leading companies. SUBSCRIBE NOW!!!
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
